Intensity Therapeutics (INTS) Current Assets (2022 - 2026)
Intensity Therapeutics' (INTS) quarterly Current Assets came in at $10.9 million in Q1 2026, up 560.57% YoY from $1.7 million in Q1 2025, and down 14.19% on a QoQ basis from $12.7 million in Q4 2025.
Intensity Therapeutics (INTS) Current Assets (2022 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 5 years of Current Assets data on file, last reported at $10.9 million in Q1 2026.
- Quarterly Current Assets rose 560.57% year-over-year to $10.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.9 million (up 560.57% YoY) and the FY2025 annual result came in at $12.7 million, up 277.91% from the prior year.
- Current Assets eased to $10.9 million in Q1 2026, from $12.7 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $18.1 million in Q2 2023 to a low of $1.5 million in Q4 2022.
- A 5-year average of $8.8 million and a median of $8.2 million in 2025 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2023 — Current Assets soared 965.75% — and 2025, when it tumbled 85.22%.
- Tracing INTS's Current Assets over 5 years: stood at $1.5 million in 2022, then soared by 965.75% to $15.5 million in 2023, then sank by 78.25% to $3.4 million in 2024, then soared by 277.91% to $12.7 million in 2025, then decreased by 14.19% to $10.9 million in 2026.
- The last three Current Assets figures came in at $10.9 million (Q1 2026), $12.7 million (Q4 2025), and $8.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 1.76 Bn |
| 10 | Intensity Therapeutics | 12.80 Mn | 12.80 Mn | - | 11.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.23 Mn |
| Mar 31, 2026 | 10.91 Mn |
| Dec 31, 2025 | 12.71 Mn |
| Sep 30, 2025 | 8.19 Mn |
| Jun 30, 2025 | 3.04 Mn |
| Mar 31, 2025 | 1.65 Mn |
| Dec 31, 2024 | 3.36 Mn |
| Sep 30, 2024 | 3.79 Mn |
| Jun 30, 2024 | 7.44 Mn |
| Mar 31, 2024 | 11.17 Mn |
| Dec 31, 2023 | 15.46 Mn |
| Sep 30, 2023 | 16.63 Mn |
| Jun 30, 2023 | 18.06 Mn |
| Dec 31, 2022 | 1.45 Mn |